Definium's LSD therapy shows anxiety relief in second Phase 3 trial

Definium's LSD-based therapy met its primary endpoint in a second large trial, reducing anxiety symptoms. This corroborates earlier efficacy signals and moves psychedelic treatments closer to regulatory approval. The result is significant for the emerging psychedelic therapeutics sector, though long-term safety and FDA review remain pending.